司美格鲁肽治疗2型糖尿病的快速卫生技术评估

Rapid Health Technology Assessment of Semaglutide in Treatment of Type 2 Diabetes Mellitus

目的 采用快速卫生技术评估评价司美格鲁肽治疗2型糖尿病的有效性、安全性和经济性。方法 检索Embase、PubMed、the Cochrane Library、中国知网、万方数据库和卫生技术评估相关的网站。由2名评价者独立地根据纳入、排除标准筛选文献,提取数据,评价文献质量并进行分析。结果 共纳入12篇系统评价/meta分析,13篇药物经济学研究。结果显示,在有效性方面,司美格鲁肽能够显著降低HbA1c、FPG和SBP水平,并减轻体质量;在安全性方面,司美格鲁肽的胃肠道不良反应发生率相对更高,同时司美格鲁肽并不会增加低血糖和急性胰腺炎的发生率;在经济性方面,司美格鲁肽能够延长患者的质量调整生命年,其增量成本效果比低于所在国家的意愿支付阈值,具有成本效果优势。结论司美格鲁肽治疗2型糖尿病具有较好的有效性、安全性和经济性。

OBJECTIVE To evaluate the efficacy, safety and economy of semaglutide in treatment of type 2 diabetes mellitus by rapid health technology assessment. METHODS Systematic retrieval of Embase, PubMed, the Cochrane Library,CNKI, Wanfang datebases and health technology assessment related websites. Two reviewers independently selected articles according to the inclusion and exclusion criteria, extracted data, evaluated article quality and performed analysis. RESULTS A total of 12 systematic/meta-analyses and 13 economic evaluations were included. The results showed that semaglutide could significantly decease the level of HbA1c, FPG, SBP and reduce weight in terms of effectiveness. In terms of safety, semaglutide increased the incidence of gastrointestinal adverse, but not increased the incidence of hypoglycemia and acute pancreatitis. In terms of economy, semaglutide could prolong quality-adjusted life years(QALYs) and had a good cost-effectiveness. Meanwile,the incremental cost-effectiveness ratio of semaglutide belowed the willingness-to-pay threshold. CONCLUSION Semaglutide has good efficacy, safety and economic in treatment of type 2 diabetes mellitus.